Panzyga Study

Panzyga Study

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
Immune Thrombocytopenia (ITP) is a blood disorder in which the immune system produces antibodies that attack and destroy the body's own blood platelets. The Panzyga Study is looking at a potential medicine (experimental drug) to see if it can result in increasing platelet counts and may potentially treat ITP. You will be infused with the experimental drug once or twice during the treatment period and will be followed up for 32 days. Testing will include blood tests, urine tests, pregnancy tests and physical exams.You may be able to take part in the study if you are below 18 years of age and have been diagnosed with chronic ITP.

Eligibility and criteria
IRB Number:
19-016318
Eligible age range:
1 years - 17.5 years
Clinical trial phase:
Phase IV
Official title:
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients with Chronic Immune Thrombocytopenia (ITP).

What to expect

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.